Hypertriglyceridemia

Hypertriglyceridemia is a metabolic disorder characterized by an abnormal elevation of triglyceride (TG) concentrations in the blood. In veterinary medicine, it is most commonly recognized in dogs and cats, and can be either a primary (idiopathic or familial) condition or secondary to other diseases such as endocrinopathies (e.g., diabetes mellitus, hypothyroidism, hyperadrenocorticism), obesity, or dietary factors. Triglycerides are a major form of lipid transported in the blood, primarily within chylomicrons and very low-density lipoproteins (VLDL). Physiologically, triglycerides serve as an energy source and are stored in adipose tissue. Hypertriglyceridemia is clinically significant because it can lead to pancreatitis, lipemia retinalis, and other systemic complications. The condition is often asymptomatic but may be detected incidentally on routine biochemistry panels. In severe cases, it can cause abdominal pain, vomiting, and neurological signs due to hyperviscosity. The classification of hypertriglyceridemia in veterinary patients is based on the underlying cause: primary (genetic) or secondary (acquired). Primary hypertriglyceridemia is well-documented in Miniature Schnauzers and is suspected to have a hereditary basis. Secondary hypertriglyceridemia is more common and is associated with conditions that increase hepatic VLDL production or decrease lipoprotein lipase activity. The diagnosis is based on fasting serum triglyceride measurements, with values > 150 mg/dL in dogs and > 100 mg/dL in cats considered elevated, though reference ranges vary by laboratory. Management focuses on treating the underlying cause, dietary modification, and in some cases, pharmacological intervention with omega-3 fatty acids or fibrates.

The etiology of hypertriglyceridemia can be divided into primary (genetic) and secondary (acquired) causes. Primary hypertriglyceridemia is an inherited disorder of lipid metabolism, most notably reported in Miniature Schnauzers, where it is transmitted as an autosomal recessive trait. A genetic mutation affecting lipoprotein lipase (LPL) or apolipoprotein C-II (apoC-II) has been hypothesized, but the exact molecular defect remains unidentified in most cases. Other breeds, such as Beagles, Shetland Sheepdogs, and Poodles, may also have a genetic predisposition. Secondary hypertriglyceridemia arises from conditions that increase triglyceride synthesis or impair clearance. Endocrine disorders are the most common secondary causes: diabetes mellitus (due to insulin deficiency or resistance leading to increased lipolysis and hepatic VLDL production), hypothyroidism (reduced LPL activity and decreased clearance of triglyceride-rich lipoproteins), hyperadrenocorticism (cortisol-induced insulin resistance and increased hepatic lipogenesis), and acromegaly (growth hormone excess). Obesity is a major contributing factor, as it increases the release of free fatty acids and promotes insulin resistance. Dietary factors, such as high-fat diets or excessive caloric intake, can also elevate triglyceride levels. Other secondary causes include pancreatitis (both as a cause and consequence), cholestatic liver disease, nephrotic syndrome (due to increased hepatic lipoprotein synthesis), and certain medications such as glucocorticoids and phenobarbital. In cats, hypertriglyceridemia is often associated with diabetes mellitus, obesity, and hepatic lipidosis. Rarely, hyperlipidemia can be due to a defect in lipoprotein metabolism, such as familial hyperchylomicronemia in cats.

Hypertriglyceridemia is a common lipid disorder in dogs and cats, though exact prevalence rates are not well-established. In dogs, primary hypertriglyceridemia is most frequently diagnosed in Miniature Schnauzers, with studies reporting a prevalence of up to 30-40% in this breed. It is also seen in other breeds such as Beagles, Shetland Sheepdogs, and Poodles, but with lower frequency. The condition is typically diagnosed in middle-aged to older dogs, with a median age of 6-8 years. There is no strong sex predilection, though some studies suggest a slight male predominance. Secondary hypertriglyceridemia is more common than the primary form and can occur in any breed, but is particularly associated with breeds predisposed to endocrinopathies, such as the Miniature Poodle (hypothyroidism), Dachshund (hyperadrenocorticism), and Labrador Retriever (obesity). In cats, hypertriglyceridemia is less commonly reported as a primary disorder, but secondary hypertriglyceridemia is frequently seen in cats with diabetes mellitus, obesity, and hepatic lipidosis. The prevalence of hypertriglyceridemia in cats with diabetes mellitus is estimated to be 50-70%. Geographic variation is not significant, but the condition is more commonly diagnosed in countries with high rates of pet obesity. Seasonal factors are not relevant. The condition is often underdiagnosed because it is asymptomatic in many cases, and routine screening is not performed unless there is a clinical suspicion or concurrent disease.

The pathophysiology of hypertriglyceridemia involves an imbalance between triglyceride production and clearance. Triglycerides are synthesized in the liver and intestine and are transported in the blood within chylomicrons (from intestinal absorption) and very low-density lipoproteins (VLDL) (from hepatic synthesis). The enzyme lipoprotein lipase (LPL), located on the endothelial surface of capillaries in adipose tissue and skeletal muscle, hydrolyzes triglycerides in chylomicrons and VLDL, releasing free fatty acids for cellular uptake. In primary hypertriglyceridemia, a genetic defect in LPL or its cofactor apoC-II leads to reduced enzyme activity, resulting in impaired clearance of triglyceride-rich lipoproteins and subsequent accumulation in the blood. In secondary hypertriglyceridemia, the underlying disease disrupts this balance. For example, in diabetes mellitus, insulin deficiency or resistance reduces LPL activity and increases hormone-sensitive lipase activity in adipose tissue, leading to increased lipolysis and free fatty acid release. The liver then takes up these free fatty acids and synthesizes more VLDL, increasing triglyceride production. In hypothyroidism, reduced thyroid hormone levels decrease LPL synthesis and activity, impairing triglyceride clearance. Hyperadrenocorticism causes insulin resistance and increased hepatic lipogenesis, leading to increased VLDL production. Obesity is associated with insulin resistance and increased free fatty acid flux, further promoting hepatic VLDL synthesis. The accumulation of triglycerides in the blood can lead to hyperviscosity, which may cause clinical signs such as abdominal pain, vomiting, and neurological disturbances. Additionally, high triglyceride levels can precipitate pancreatitis, as the release of free fatty acids from triglycerides by pancreatic lipase can cause acinar cell damage and inflammation. Chronic hypertriglyceridemia may also contribute to atherosclerosis, though this is less common in dogs and cats than in humans. In cats, severe hypertriglyceridemia can lead to hepatic lipidosis, as the liver accumulates triglycerides, impairing hepatic function.

Predisposing factors for hypertriglyceridemia include both intrinsic and extrinsic elements. Intrinsic factors include genetic predisposition, as seen in Miniature Schnauzers and other breeds with familial hypertriglyceridemia. Age is a significant factor, as the condition is more common in middle-aged to older animals, likely due to the increased prevalence of secondary causes such as endocrinopathies and obesity. Sex may play a role, with some studies suggesting a higher incidence in males, but this is not consistent. Extrinsic factors include diet, particularly high-fat diets or excessive caloric intake, which can increase triglyceride synthesis and impair clearance. Obesity is a major predisposing factor, as it is associated with insulin resistance and increased free fatty acid flux. Concurrent diseases, such as diabetes mellitus, hypothyroidism, hyperadrenocorticism, pancreatitis, and nephrotic syndrome, are strong predisposing factors. Certain medications, including glucocorticoids, phenobarbital, and estrogen-containing compounds, can also induce hypertriglyceridemia. In cats, obesity and diabetes mellitus are the most common predisposing factors. Management of these underlying conditions is crucial for the resolution of hypertriglyceridemia.

Clinical signs of hypertriglyceridemia are often absent, and the condition is frequently an incidental finding on routine blood work. When clinical signs do occur, they are typically related to the severity of the hypertriglyceridemia or to the underlying cause. In dogs, the most common clinical sign is abdominal pain, which may be due to pancreatitis, a frequent complication. Vomiting, diarrhea, and anorexia may also be observed. In severe cases, lipemia retinalis (a milky appearance of the retinal vessels) can be seen on ophthalmic examination, and xanthomas (cholesterol deposits in the skin) may develop. Neurological signs, such as seizures or peripheral neuropathy, can occur due to hyperviscosity or microthromboembolism. In cats, hypertriglyceridemia is often associated with hepatic lipidosis, which presents with anorexia, weight loss, icterus, and hepatomegaly. Cats with diabetes mellitus may show polyuria, polydipsia, and weight loss. Physical examination may reveal obesity, hepatomegaly, or signs of pancreatitis, such as cranial abdominal pain. In chronic cases, there may be evidence of atherosclerosis, though this is rare. The clinical signs are often more pronounced in animals with secondary hypertriglyceridemia, as the underlying disease contributes to the clinical picture.

The differential diagnoses for hypertriglyceridemia include conditions that can cause elevated triglyceride levels or mimic its clinical signs. Key differentials include: 1) Diabetes mellitus: Characterized by persistent hyperglycemia, glycosuria, and elevated fructosamine levels. Insulin deficiency or resistance leads to increased lipolysis and hepatic VLDL production. 2) Hypothyroidism: Typically presents with lethargy, weight gain, dermatological changes, and a low total T4 and free T4 by equilibrium dialysis. Reduced LPL activity impairs triglyceride clearance. 3) Hyperadrenocorticism: Clinical signs include polyuria, polydipsia, polyphagia, abdominal distension, and bilaterally symmetric alopecia. Cortisol excess causes insulin resistance and increased hepatic lipogenesis. Diagnosis is confirmed with ACTH stimulation test or low-dose dexamethasone suppression test. 4) Pancreatitis: Acute or chronic inflammation of the pancreas, often presenting with vomiting, abdominal pain, and elevated pancreatic lipase immunoreactivity (cPLI or fPLI). Hypertriglyceridemia can be both a cause and consequence of pancreatitis. 5) Nephrotic syndrome: Proteinuria, hypoalbuminemia, and edema. Increased hepatic lipoprotein synthesis due to protein loss leads to hyperlipidemia. 6) Cholestatic liver disease: Elevated liver enzymes, hyperbilirubinemia, and increased bile acids. Impaired lipid metabolism can cause hypertriglyceridemia. 7) Obesity: A common cause of secondary hypertriglyceridemia, often associated with insulin resistance. 8) Dietary indiscretion or high-fat diet: Recent ingestion of a fatty meal can cause transient hypertriglyceridemia. 9) Drug-induced: Glucocorticoids, phenobarbital, and other medications can elevate triglycerides. 10) Familial hyperchylomicronemia in cats: A rare genetic disorder causing severe hypertriglyceridemia and lipemia. Differentiation requires a thorough history, physical examination, and diagnostic testing, including fasting triglyceride levels, complete blood count, serum biochemistry, urinalysis, and specific endocrine tests.

The diagnostic approach to hypertriglyceridemia should be systematic. Step 1: Obtain a thorough history and physical examination, with attention to diet, medications, and clinical signs. Step 2: Confirm hypertriglyceridemia with a fasting serum triglyceride measurement. The patient should be fasted for 12 hours to avoid postprandial lipemia. A triglyceride level > 150 mg/dL in dogs and > 100 mg/dL in cats is considered elevated, but reference ranges vary. If the sample is lipemic, it may interfere with other biochemical assays. Step 3: Perform a complete blood count, serum biochemistry profile, and urinalysis to screen for underlying diseases. This should include glucose, fructosamine, total T4, cortisol, liver enzymes, bile acids, and urine protein-to-creatinine ratio. Step 4: If diabetes mellitus is suspected, confirm with persistent hyperglycemia, glycosuria, and elevated fructosamine. Step 5: If hypothyroidism is suspected, measure total T4 and free T4 by equilibrium dialysis; a low total T4 with a low free T4 is supportive. Step 6: If hyperadrenocorticism is suspected, perform an ACTH stimulation test or low-dose dexamethasone suppression test. Step 7: If pancreatitis is suspected, measure pancreatic lipase immunoreactivity (cPLI or fPLI) and consider abdominal ultrasound. Step 8: If nephrotic syndrome is suspected, evaluate proteinuria and serum albumin. Step 9: If no secondary cause is identified, consider primary hypertriglyceridemia, especially in predisposed breeds. Step 10: In cases of severe hypertriglyceridemia or if there is a concern for genetic causes, consider advanced lipid profiling or genetic testing if available. The diagnostic algorithm should be tailored to the individual patient based on clinical signs and risk factors.

Laboratory findings in hypertriglyceridemia are primarily characterized by elevated serum triglyceride levels. The most common finding is a lipemic serum sample, which appears milky or turbid. Hematology may be normal, but in cases of pancreatitis, there may be leukocytosis with a left shift. Serum biochemistry may reveal elevated liver enzymes (ALT, ALP) if there is concurrent hepatic lipidosis or cholestasis. In diabetes mellitus, hyperglycemia and elevated fructosamine are present. In hypothyroidism, total T4 and free T4 are decreased. In hyperadrenocorticism, there may be elevated ALP, hypercholesterolemia, and a stress leukogram. Urinalysis may show glycosuria in diabetes mellitus and proteinuria in nephrotic syndrome. Blood gas analysis may reveal metabolic acidosis in cases of severe pancreatitis or diabetic ketoacidosis. Specific biomarkers include pancreatic lipase immunoreactivity (cPLI or fPLI) for pancreatitis, which is often elevated. In cats, fPLI is useful. Additionally, serum cholesterol may be elevated concurrently. In cases of primary hypertriglyceridemia, other laboratory parameters are typically normal. It is important to note that lipemia can interfere with many biochemical assays, including electrolytes, enzymes, and bilirubin, so samples should be handled appropriately, such as fasting and centrifugation to remove chylomicrons.

Imaging findings in hypertriglyceridemia are not specific but may reveal changes associated with underlying conditions. Abdominal radiography may show a loss of serosal detail in cases of pancreatitis, or hepatomegaly in cases of hepatic lipidosis. Thoracic radiography may be normal, but in rare cases of atherosclerosis, there may be evidence of vascular mineralization. Abdominal ultrasonography is more useful and may reveal changes consistent with pancreatitis, such as an enlarged, hypoechoic pancreas with surrounding hyperechoic mesentery. In hepatic lipidosis, the liver may appear hyperechoic and enlarged. Ultrasonography can also help evaluate the adrenal glands for hyperadrenocorticism and the kidneys for nephrotic syndrome. Computed tomography (CT) and magnetic resonance imaging (MRI) are not routinely used for hypertriglyceridemia but may be indicated to evaluate for pancreatitis or other abdominal pathology. Echocardiography may be performed if there is suspicion of atherosclerosis or cardiac disease, but this is rare. Endoscopy is not typically used. Imaging is primarily directed at identifying the underlying cause of hypertriglyceridemia.

Cytology and histopathology are not typically required for the diagnosis of hypertriglyceridemia, but they may be useful in certain situations. Fine needle aspirate (FNA) of the liver may be performed in cases of suspected hepatic lipidosis, revealing hepatocytes with cytoplasmic vacuolization due to lipid accumulation. FNA of subcutaneous xanthomas may show lipid-laden macrophages. Histopathology of the liver in hepatic lipidosis shows marked hepatocellular vacuolation with lipid, which can be confirmed with special stains such as Oil Red O. In cases of pancreatitis, histopathology of the pancreas may show acinar cell necrosis, inflammation, and fibrosis. However, these procedures are invasive and are usually reserved for cases where the diagnosis is uncertain or when there is a need to assess the severity of organ damage. In most cases, the diagnosis of hypertriglyceridemia is based on laboratory findings, and cytology/histopathology is not necessary.

The treatment of hypertriglyceridemia depends on the underlying cause and the severity of the condition. The primary goal is to manage any secondary disease, such as diabetes mellitus, hypothyroidism, or hyperadrenocorticism. In cases of primary hypertriglyceridemia, treatment focuses on dietary modification and, if necessary, pharmacological intervention. Dietary management is the cornerstone of therapy. A low-fat, high-fiber diet is recommended, with fat content typically less than 10-15% on a dry matter basis. The diet should be fed in multiple small meals to reduce postprandial lipemia. Weight loss is essential in obese animals. Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) are often recommended at a dose of 100-200 mg/kg of combined EPA and DHA per day, as they can reduce triglyceride synthesis. In dogs, fish oil supplements are commonly used. If dietary management is insufficient, pharmacological agents may be considered. Fibrates, such as gemfibrozil (5-10 mg/kg PO q12h) or fenofibrate (3-5 mg/kg PO q24h), can be used to reduce triglyceride levels by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha). However, these drugs are not commonly used in veterinary medicine due to potential side effects, including hepatotoxicity and gastrointestinal upset. Niacin (vitamin B3) has also been used, but its efficacy and safety in dogs and cats are not well-established. In cases of severe hypertriglyceridemia with pancreatitis, aggressive fluid therapy, pain management, and nutritional support are necessary. In cats with hepatic lipidosis, aggressive nutritional support with a feeding tube is critical. The treatment plan should be individualized based on the patient's condition and response to therapy.

The prognosis for hypertriglyceridemia depends on the underlying cause and the presence of complications. In cases of primary hypertriglyceridemia, the condition is often manageable with dietary modification and, if needed, pharmacological therapy. The prognosis is generally good if the condition is detected early and managed appropriately. However, if left untreated, hypertriglyceridemia can lead to recurrent pancreatitis, which can be life-threatening. In cases of secondary hypertriglyceridemia, the prognosis is largely determined by the underlying disease. For example, if diabetes mellitus is well-controlled, hypertriglyceridemia may resolve. If hypothyroidism is treated with thyroid hormone replacement, triglyceride levels typically normalize. Hyperadrenocorticism, if managed with appropriate therapy (e.g., trilostane or mitotane), can also lead to resolution of hypertriglyceridemia. However, if the underlying disease is poorly controlled or if complications such as pancreatitis or hepatic lipidosis develop, the prognosis is more guarded. In cats with hepatic lipidosis, the prognosis is good with aggressive nutritional support, with survival rates of 80-90% reported. Overall, the prognosis is favorable with early diagnosis and appropriate management.

Follow-up for hypertriglyceridemia involves regular monitoring of serum triglyceride levels and assessment of the underlying condition. Initially, triglyceride levels should be rechecked 2-4 weeks after initiating dietary or pharmacological therapy. If the levels are decreasing, the frequency of monitoring can be reduced to every 3-6 months. In cases of secondary hypertriglyceridemia, monitoring should also include assessment of the underlying disease, such as blood glucose and fructosamine for diabetes mellitus, thyroid hormone levels for hypothyroidism, and cortisol levels for hyperadrenocorticism. Body weight should be monitored regularly, especially in obese animals. If the patient is on pharmacological therapy, such as fibrates, liver enzymes should be monitored periodically to detect potential hepatotoxicity. In cases of pancreatitis, follow-up should include monitoring of pancreatic lipase immunoreactivity and clinical signs. Long-term management may require ongoing dietary modification and weight control. Owners should be educated about the importance of compliance with dietary recommendations and medication administration. If the patient develops clinical signs such as vomiting or abdominal pain, immediate veterinary attention is warranted.

Clinical Pearls: 1) Always obtain a fasting blood sample for triglyceride measurement, as postprandial lipemia can falsely elevate levels. 2) In Miniature Schnauzers, hypertriglyceridemia is common and may be an incidental finding; however, it can predispose to pancreatitis, so it should be managed proactively. 3) In cats, hypertriglyceridemia is often associated with hepatic lipidosis, so any cat with anorexia and hypertriglyceridemia should be evaluated for hepatic lipidosis. 4) Omega-3 fatty acids are a safe and effective adjunctive therapy for hypertriglyceridemia. 5) Treating the underlying endocrinopathy often resolves hypertriglyceridemia without the need for lipid-lowering drugs. Clinical Pitfalls: 1) Failing to fast the patient before blood collection can lead to a misdiagnosis of hypertriglyceridemia. 2) Overlooking secondary causes, such as hypothyroidism or hyperadrenocorticism, can lead to ineffective treatment. 3) Using lipid-lowering drugs without addressing the underlying cause is unlikely to be successful. 4) In cats, aggressive weight loss can precipitate hepatic lipidosis, so weight loss should be gradual. 5) Ignoring the potential for pancreatitis in patients with severe hypertriglyceridemia can lead to a life-threatening complication.

Pharmacological management of hypertriglyceridemia is typically reserved for cases that do not respond to dietary modification or when there is a high risk of pancreatitis. The following drug protocols are based on Plumb's Veterinary Drug Handbook: 1) Omega-3 fatty acids (fish oil): Dogs: 100-200 mg/kg of combined EPA and DHA PO q24h. Cats: 100-200 mg/kg PO q24h. Available as capsules or liquid. May cause gastrointestinal upset; administer with food. 2) Gemfibrozil: Dogs: 5-10 mg/kg PO q12h. Cats: 5-10 mg/kg PO q12h (limited data). Monitor liver enzymes and triglycerides. Contraindicated in hepatic or renal impairment. 3) Fenofibrate: Dogs: 3-5 mg/kg PO q24h. Cats: 3-5 mg/kg PO q24h (limited data). Monitor for hepatotoxicity and myopathy. 4) Niacin (nicotinic acid): Dogs: 25-100 mg/kg PO q24h (not commonly used). Cats: Not recommended. May cause flushing and hepatotoxicity. 5) Statins (e.g., atorvastatin): Not routinely used in veterinary medicine due to limited efficacy and potential toxicity. 6) In cases of pancreatitis, treatment includes IV fluid therapy (e.g., lactated Ringer's solution at 60-100 ml/kg/day), analgesics (e.g., buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h), antiemetics (e.g., maropitant 1 mg/kg SC q24h), and nutritional support (e.g., early enteral feeding). 7) For hepatic lipidosis in cats, nutritional support with a feeding tube is essential, along with hepatoprotectants such as S-adenosylmethionine (SAMe) at 20 mg/kg PO q24h and vitamin E at 10-20 IU/kg PO q24h. All drug dosages should be adjusted based on renal and hepatic function, and patients should be monitored for adverse effects.

Evidence-based literature on hypertriglyceridemia in veterinary medicine is limited but growing. Key studies include: 1) A study by Xenoulis et al. (2007) evaluated the prevalence of hypertriglyceridemia in Miniature Schnauzers and found that it is a common inherited disorder, with affected dogs having significantly higher triglyceride levels than unaffected dogs. 2) A study by Kluger et al. (2010) investigated the association between hypertriglyceridemia and pancreatitis in dogs, concluding that hypertriglyceridemia is a risk factor for pancreatitis. 3) A study by Zoran (2010) reviewed the management of hyperlipidemia in dogs and cats, emphasizing the importance of dietary modification and omega-3 fatty acid supplementation. 4) A study by Webb and Smith (2014) evaluated the use of gemfibrozil in dogs with hypertriglyceridemia and found it to be effective in reducing triglyceride levels, but with potential side effects. 5) A study by Armstrong and Specht (2015) reviewed the pathophysiology and treatment of hyperlipidemia in cats, highlighting the association with hepatic lipidosis and the importance of nutritional support. 6) Consensus guidelines from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and management of hyperlipidemia in dogs and cats were published in 2019, providing evidence-based recommendations for diagnosis, treatment, and monitoring. These guidelines recommend a stepwise approach, starting with dietary modification and adding pharmacological therapy if necessary. Overall, the evidence supports the importance of identifying and treating underlying causes, as well as the use of omega-3 fatty acids and fibrates in refractory cases.